Table 1 Patient characteristics.

From: Impaired mitochondrial oxidative phosphorylation capacity in epicardial adipose tissue is associated with decreased concentration of adiponectin and severity of coronary atherosclerosis

 

Non-CAD (n = 11)

CAD (n = 14)

P value

Age, yrs

68 ± 14

68 ± 11

0.99

Male/female

4/7

8/6

0.30

BMI, kg/m2

23.6 ± 4.2

24.3 ± 3.6

0.66

Visceral abdominal fat area, cm2

62.1 ± 49.9

96.9 ± 44.0

0.08

LVEF, %

56 ± 16

50 ± 15

0.37

CAD

  1-vessel disease

0 (0)

2 (14)

 

  2-vessel disease

0 (0)

4 (29)

 

  3-vessel disease

0 (0)

8 (57)

 

Complications

  Hypertension

6 (55)

10 (71)

0.38

  Diabetes mellitus

2 (18)

11 (79)

0.003

  Dyslipidemia

2 (18)

13 (93)

<0.001

Medication

  β-blocker

4 (36)

8 (57)

0.30

  ACE inhibitor or ARB

4 (36)

9 (64)

0.24

  Statins

2 (18)

14 (100)

<0.001

  Antidiabetics

2 (18)

6 (43)

0.19

HbA1c, %

5.6 ± 0.3

7.2 ± 1.3

<0.001

Triglyceride, mmol/L

1.58 ± 1.31

1.32 ± 0.12

0.63

HDL-cholesterol, mmol/L

1.47 ± 0.50

1.26 ± 0.29

0.22

LDL-cholesterol, mmol/L

2.58 ± 0.95

2.46 ± 0.79

0.75

Serum adiponectin, µg/mL

12.3 ± 5.6

4.6 ± 4.0

<0.001

  1. Values are mean ± SD or n (%). ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction.